Idiopathic Membranous Nephropathy Market Size, Epidemiology, Treatment, Therapies, and Companies by DelveInsight

February 17 10:30 2022
Idiopathic Membranous Nephropathy Market Size, Epidemiology, Treatment, Therapies, and Companies by DelveInsight
Idiopathic Membranous Nephropathy Market

DelveInsight’s “Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Idiopathic Membranous Nephropathy Market are:

  • North America is expected to hold the dominant position in the global idiopathic membranous nephropathy market due to high prevalence of idiopathic membranous nephropathy in the region.
  • According to the clinical journal of American Society of Nephrology, 2017, around 12 million people in the age group of 50 to 60 suffer from idiopathic membranous nephropathy every year in North America.
  • National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network and GlaxoSmithline are currently working together to understand the effect of combination therapy involving belimumab and rituximab on patients suffering from idiopathic membranous nephropathy. The phase II study started in December 2019 and is expected to finish in February 2025.
  • According to the New England Journal of Medicine, 2019, a clinical trial performed on patients suffering from membranous nephropathy to compare the efficacy of rituximab and cyclosporine, showed that 60% of the patients responded positively to the rituximab treatment. The remaining 40% patients did not show any response to the treatment.

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market

 

Membranous nephropathy occurs when the blood vessels in the nephron (filters) of the kidney get damaged. This leads to proteinuria, that is, leakage of proteins in the urine due to thickening of the walls of the blood vessels which increase the chances of kidney failure. There is no specific treatment available for the condition but if treated correctly, it can be controlled. The symptoms include swelling in the legs, weight gain, poor appetite, high cholesterol, fatigue, acute and chronic kidney failure. Two types of membranous nephropathy are primary and secondary membranous nephropathy. Primary membranous nephropathy occurs when the body‘s antibodies attack healthy cells in the body, and secondary membranous nephropathy occurs due to conditions like hepatitis B, hepatitis C, syphilis, internalization of medications like NSAIDs, gold salts, tumors etc.

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market

 

Idiopathic Membranous Nephropathy Drugs covered

1. Olinvo (Oliceridine injection or TRV130)

2. HTX011

3. CR845/Difelikefalin

4. NTM001

5. PF05089771

And many others

 

Some of Idiopathic Membranous Nephropathy Companies are:

1. Trevena

2. Heron Therapeutics

3. Cara Therapeutics

4. Neumentum Pharmaceuticals

5. Pfizer

And many others

 

Table of Contents:

1. Key Insights

2. Executive Summary of Idiopathic Membranous Nephropathy

3. Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy

4. Idiopathic Membranous Nephropathy: Market Overview at a Glance

5. Idiopathic Membranous Nephropathy: Disease Background and Overview

6. Patient Journey

7. Idiopathic Membranous Nephropathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Idiopathic Membranous Nephropathy Unmet Needs

10. Key Endpoints of Idiopathic Membranous Nephropathy Treatment

11. Idiopathic Membranous Nephropathy Marketed Products

List to be continued in report

12. Idiopathic Membranous Nephropathy Emerging Therapies

List to be continued in report

13. Idiopathic Membranous Nephropathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Idiopathic Membranous Nephropathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-market